Azithromycin alters macrophage phenotype

Brian S. Murphy, Vidya Sundareshan, Theodore Cory, Don Hayes, Michael I. Anstead, David J. Feola

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Objectives: To investigate the in vitro effects of azithromycin on macrophage phenotype. Utilizing a mouse macrophage cell line (J774), we examined the effect of azithromycin on the properties that define classical macrophage activation (M1) and alternative macrophage activation (M2). Methods: J774 cells were cultured in the presence of azithromycin and stimulated with classical activation [interferon-γ (IFNγ)] and alternative activation [interleukin (IL)-4 and IL-13] cytokines along with lipopolysaccharide (LPS). Macrophages were analysed for inflammatory cytokine production, surface receptor expression, inducible nitric oxide synthase (iNOS) protein expression and arginase activity. Results: Azithromycin altered the overall macrophage phenotype. Azithromycin-treated J774 macrophages demonstrated a significantly reduced production of the pro-inflammatory cytokines IL-12 and IL-6, increased production of the anti-inflammatory cytokine IL-10 and decreased the ratio of IL-12 to IL-10 by 60%. Receptor expression indicative of the M2 phenotype (mannose receptor and CD23) was increased, and receptor expression typically up-regulated in M1 cells (CCR7) was inhibited. The presence of azithromycin increased arginase (M2 effector molecule) activity 10-fold in cells stimulated with IFNγ and LPS, and iNOS protein (M1 effector molecule) concentrations were attenuated by the drug. Conclusions: These data provide evidence that azithromycin affects the inflammatory process at the level of the macrophage and shifts macrophage polarization towards the alternatively activated phenotype. This recently defined M2 phenotype has been described in conditions in which pulmonary inflammation and fibrosis are major determinants of clinical outcome, but the concept of antibiotics altering macrophage phenotype has not yet been critically evaluated.

Original languageEnglish (US)
Pages (from-to)554-560
Number of pages7
JournalJournal of Antimicrobial Chemotherapy
Volume61
Issue number3
DOIs
StatePublished - Mar 1 2008

Fingerprint

Azithromycin
Macrophages
Phenotype
Cytokines
Arginase
Macrophage Activation
Nitric Oxide Synthase Type II
Interleukin-12
Interleukin-10
Interferons
Lipopolysaccharides
Interleukin-13
Pulmonary Fibrosis
Interleukin-4
Cultured Cells
Interleukin-6
Pneumonia
Proteins
Anti-Inflammatory Agents
Anti-Bacterial Agents

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Murphy, B. S., Sundareshan, V., Cory, T., Hayes, D., Anstead, M. I., & Feola, D. J. (2008). Azithromycin alters macrophage phenotype. Journal of Antimicrobial Chemotherapy, 61(3), 554-560. https://doi.org/10.1093/jac/dkn007

Azithromycin alters macrophage phenotype. / Murphy, Brian S.; Sundareshan, Vidya; Cory, Theodore; Hayes, Don; Anstead, Michael I.; Feola, David J.

In: Journal of Antimicrobial Chemotherapy, Vol. 61, No. 3, 01.03.2008, p. 554-560.

Research output: Contribution to journalArticle

Murphy, BS, Sundareshan, V, Cory, T, Hayes, D, Anstead, MI & Feola, DJ 2008, 'Azithromycin alters macrophage phenotype', Journal of Antimicrobial Chemotherapy, vol. 61, no. 3, pp. 554-560. https://doi.org/10.1093/jac/dkn007
Murphy BS, Sundareshan V, Cory T, Hayes D, Anstead MI, Feola DJ. Azithromycin alters macrophage phenotype. Journal of Antimicrobial Chemotherapy. 2008 Mar 1;61(3):554-560. https://doi.org/10.1093/jac/dkn007
Murphy, Brian S. ; Sundareshan, Vidya ; Cory, Theodore ; Hayes, Don ; Anstead, Michael I. ; Feola, David J. / Azithromycin alters macrophage phenotype. In: Journal of Antimicrobial Chemotherapy. 2008 ; Vol. 61, No. 3. pp. 554-560.
@article{06fd14c46b924f86b9bd988c2f939216,
title = "Azithromycin alters macrophage phenotype",
abstract = "Objectives: To investigate the in vitro effects of azithromycin on macrophage phenotype. Utilizing a mouse macrophage cell line (J774), we examined the effect of azithromycin on the properties that define classical macrophage activation (M1) and alternative macrophage activation (M2). Methods: J774 cells were cultured in the presence of azithromycin and stimulated with classical activation [interferon-γ (IFNγ)] and alternative activation [interleukin (IL)-4 and IL-13] cytokines along with lipopolysaccharide (LPS). Macrophages were analysed for inflammatory cytokine production, surface receptor expression, inducible nitric oxide synthase (iNOS) protein expression and arginase activity. Results: Azithromycin altered the overall macrophage phenotype. Azithromycin-treated J774 macrophages demonstrated a significantly reduced production of the pro-inflammatory cytokines IL-12 and IL-6, increased production of the anti-inflammatory cytokine IL-10 and decreased the ratio of IL-12 to IL-10 by 60{\%}. Receptor expression indicative of the M2 phenotype (mannose receptor and CD23) was increased, and receptor expression typically up-regulated in M1 cells (CCR7) was inhibited. The presence of azithromycin increased arginase (M2 effector molecule) activity 10-fold in cells stimulated with IFNγ and LPS, and iNOS protein (M1 effector molecule) concentrations were attenuated by the drug. Conclusions: These data provide evidence that azithromycin affects the inflammatory process at the level of the macrophage and shifts macrophage polarization towards the alternatively activated phenotype. This recently defined M2 phenotype has been described in conditions in which pulmonary inflammation and fibrosis are major determinants of clinical outcome, but the concept of antibiotics altering macrophage phenotype has not yet been critically evaluated.",
author = "Murphy, {Brian S.} and Vidya Sundareshan and Theodore Cory and Don Hayes and Anstead, {Michael I.} and Feola, {David J.}",
year = "2008",
month = "3",
day = "1",
doi = "10.1093/jac/dkn007",
language = "English (US)",
volume = "61",
pages = "554--560",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Azithromycin alters macrophage phenotype

AU - Murphy, Brian S.

AU - Sundareshan, Vidya

AU - Cory, Theodore

AU - Hayes, Don

AU - Anstead, Michael I.

AU - Feola, David J.

PY - 2008/3/1

Y1 - 2008/3/1

N2 - Objectives: To investigate the in vitro effects of azithromycin on macrophage phenotype. Utilizing a mouse macrophage cell line (J774), we examined the effect of azithromycin on the properties that define classical macrophage activation (M1) and alternative macrophage activation (M2). Methods: J774 cells were cultured in the presence of azithromycin and stimulated with classical activation [interferon-γ (IFNγ)] and alternative activation [interleukin (IL)-4 and IL-13] cytokines along with lipopolysaccharide (LPS). Macrophages were analysed for inflammatory cytokine production, surface receptor expression, inducible nitric oxide synthase (iNOS) protein expression and arginase activity. Results: Azithromycin altered the overall macrophage phenotype. Azithromycin-treated J774 macrophages demonstrated a significantly reduced production of the pro-inflammatory cytokines IL-12 and IL-6, increased production of the anti-inflammatory cytokine IL-10 and decreased the ratio of IL-12 to IL-10 by 60%. Receptor expression indicative of the M2 phenotype (mannose receptor and CD23) was increased, and receptor expression typically up-regulated in M1 cells (CCR7) was inhibited. The presence of azithromycin increased arginase (M2 effector molecule) activity 10-fold in cells stimulated with IFNγ and LPS, and iNOS protein (M1 effector molecule) concentrations were attenuated by the drug. Conclusions: These data provide evidence that azithromycin affects the inflammatory process at the level of the macrophage and shifts macrophage polarization towards the alternatively activated phenotype. This recently defined M2 phenotype has been described in conditions in which pulmonary inflammation and fibrosis are major determinants of clinical outcome, but the concept of antibiotics altering macrophage phenotype has not yet been critically evaluated.

AB - Objectives: To investigate the in vitro effects of azithromycin on macrophage phenotype. Utilizing a mouse macrophage cell line (J774), we examined the effect of azithromycin on the properties that define classical macrophage activation (M1) and alternative macrophage activation (M2). Methods: J774 cells were cultured in the presence of azithromycin and stimulated with classical activation [interferon-γ (IFNγ)] and alternative activation [interleukin (IL)-4 and IL-13] cytokines along with lipopolysaccharide (LPS). Macrophages were analysed for inflammatory cytokine production, surface receptor expression, inducible nitric oxide synthase (iNOS) protein expression and arginase activity. Results: Azithromycin altered the overall macrophage phenotype. Azithromycin-treated J774 macrophages demonstrated a significantly reduced production of the pro-inflammatory cytokines IL-12 and IL-6, increased production of the anti-inflammatory cytokine IL-10 and decreased the ratio of IL-12 to IL-10 by 60%. Receptor expression indicative of the M2 phenotype (mannose receptor and CD23) was increased, and receptor expression typically up-regulated in M1 cells (CCR7) was inhibited. The presence of azithromycin increased arginase (M2 effector molecule) activity 10-fold in cells stimulated with IFNγ and LPS, and iNOS protein (M1 effector molecule) concentrations were attenuated by the drug. Conclusions: These data provide evidence that azithromycin affects the inflammatory process at the level of the macrophage and shifts macrophage polarization towards the alternatively activated phenotype. This recently defined M2 phenotype has been described in conditions in which pulmonary inflammation and fibrosis are major determinants of clinical outcome, but the concept of antibiotics altering macrophage phenotype has not yet been critically evaluated.

UR - http://www.scopus.com/inward/record.url?scp=40049104684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40049104684&partnerID=8YFLogxK

U2 - 10.1093/jac/dkn007

DO - 10.1093/jac/dkn007

M3 - Article

VL - 61

SP - 554

EP - 560

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 3

ER -